Renal protective effects of tofogliflozin and changes in clinical parameters affecting renal function in patients with type 2 diabetes

Renal protective effects of tofogliflozin and changes in clinical parameters affecting renal function in patients with type 2 diabetes - Renoprotective effect of tofogliflozin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048277

Enrollment

150

Registered

2022-07-05

Start date

2019-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who were administered tofogliflozin

Exclusion criteria

Exclusion criteria: 1. Tofogliflozin had already administered at the initial consultation 2. Patients who discontinued treatment or who were transferred to other hospitals during the observation period 3. Patient after renal transplantation 4. Iron preparations were started during the observation period 5. GLP-1 receptor agonists were started during the observation period 6. Antihypertensive agents, diuretics or urate lowering agents were changed during the observation period

Design outcomes

Primary

Measure	Time frame
changes in estimated glomerular filtration rate before and after the initiation of tofogliflozin	—

Countries

Japan

Contacts

Public ContactHiroyuki Ito

Edogawa Hospital Department of Diabetes, Metabolism and Kidney Disease

ito@edogawa.or.jp03-3673-1221

Outcome results